title: Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
authors.forename: Ohad
authors.initials: O
authors.lastname: Benjamini
authors.forename: Preetesh
authors.initials: P
authors.lastname: Jain
authors.forename: Zeev
authors.initials: Z
authors.lastname: Estrov
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
mesh_terms: D000368:Aged; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D013163:Splenomegaly / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053613:Janus Kinase 1